Chad Young

Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT.

Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT.

Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT.

Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT.

Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT.

Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT.

Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT.